Directed evolution of brain-derived neurotrophic factor for improved folding and expression in Saccharomyces cerevisiae

Applied and Environmental Microbiology

Volumn 80, Issue 18, 2014, Pages 5732-5742

  Burns, Michael L ^a   Malott, Thomas M ^a   Metcalf, Kevin J ^a   Hackel, Benjamin J ^b   Chan, Jonah R ^c   Shusta, Eric V ^a  

^a University of Wisconsin Madison   (United States)

^b University of Minnesota   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGREGATES; AMINO ACIDS; PROTEINS;

BRAIN-DERIVED NEUROTROPHIC FACTORS; DIRECTED EVOLUTION; INSOLUBLE AGGREGATES; MICROBIAL PRODUCTION; RANDOM MUTAGENESIS; SITE DIRECTED MUTAGENESIS; THERAPEUTIC POTENTIALS; YEAST SURFACE DISPLAYS;

YEAST;

EVOLUTION; NERVOUS SYSTEM; PROTEIN; SECRETION; YEAST;

BRAIN DERIVED NEUROTROPHIC FACTOR; MEMBRANE PROTEIN; PROTEIN BINDING; PROTEIN TYROSINE KINASE; TROPOMYOSIN-RELATED KINASE-B, HUMAN;

CELL SURFACE DISPLAY; DIRECTED MOLECULAR EVOLUTION; DNA SHUFFLING; GENE EXPRESSION; GENETICS; METABOLISM; PROTEIN FOLDING; SACCHAROMYCES CEREVISIAE; SITE DIRECTED MUTAGENESIS;

BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL SURFACE DISPLAY TECHNIQUES; DIRECTED MOLECULAR EVOLUTION; DNA SHUFFLING; GENE EXPRESSION; MEMBRANE GLYCOPROTEINS; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN-TYROSINE KINASES; SACCHAROMYCES CEREVISIAE;

EID: 84906351276     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.01466-14     Document Type: Article

References (49)

1. Pezet S, Malcangio M. 2004. Brain-derived neurotrophic factor as a drug target for CNS disorders. Expert Opin. Ther. Targets 8:391-399. http://dx.doi.org/10.1517/14728222.8.5.391.
2. Tapia-Arancibia L, Rage F, Givalois L, Arancibia S. 2004. Physiology of BDNF: focus on hypothalamic function. Front. Neuroendocrinol. 25:77- 107. http://dx.doi.org/10.1016/j.yfrne.2004.04.001.
3. Zhang Y, Pardridge WM. 2006. Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion. Brain Res. 1111:227-229. http://dx.doi.org/10.1016/j.brainres.2006.07.005.
4. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, Rockenstein E, Chao MV, Koo EH, Geschwind D, Masliah E, Chiba AA, Tuszynski MH. 2009. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat. Med. 15:331-337. http://dx.doi.org/10.1038/nm.1912.
5. Tsukahara T, Takeda M, Shimohama S, Ohara O, Hashimoto N. 1995. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced Parkinsonism in monkeys. Neurosurgery 37: 733-741. http://dx.doi.org/10.1227/00006123-199510000-00018.
6. Canals JM, Pineda JR, Torres-Peraza JF, Bosch M, Martín-Ibañez R, Muñoz MT, Mengod G, Ernfors P, Alberch J. 2004. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci. 24:7727-7739. http://dx.doi.org/10.1523/JNEUROSCI.1197-04.2004.
7. Jeong HH, Piao S, Ha JN, Kim IG, Oh SH, Lee JH, Cho HJ, Hong SH, Kim SW, Lee JY. 2013. Combined therapeutic effect of udenafil and adipose-derived stem cell (ADSC)/brain-derived neurotrophic factor (BDNF)-membrane system in a rat model of cavernous nerve injury. Urology 81:1108.e7-1108.e14. http://dx.doi.org/10.1016/j.urology.2013.01.022.
8. Barbacid M. 1994. The Trk family of neurotrophin receptors. J. Neurobiol. 25:1386-1403. http://dx.doi.org/10.1002/neu.480251107.
9. Heumann R. 1994. Neurotrophin signalling. Curr. Opin. Neurobiol. 4:668-679. http://dx.doi.org/10.1016/0959-4388(94)90008-6.
10. Banfield MJ, Naylor RL, Robertson AG, Allen SJ, Dawbarn D, Brady RL. 2001. Specificity in Trk receptor:neurotrophin interactions: the crystal structure of TrkB-d5 in complex with neurotrophin-4/5. Structure 9:1191-1199. http://dx.doi.org/10.1016/S0969-2126(01)00681-5.
11. Butte MJ, Hwang PK, Mobley WC, Fletterick RJ. 1998. Crystal structure of neurotrophin-3 homodimer shows distinct regions are used to bind its receptors. Biochemistry 37:16846-16852. http://dx.doi.org/10.1021/bi981254o.
12. Wiesmann C, Ultsch MH, Bass SH, de Vos AM. 1999. Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor. Nature 401:184-188. http://dx.doi.org/10.1038/43705.
13. Colangelo AM, Finotti N, Ceriani M, Alberghina L, Martegani E, Aloe L, Lenzi L, Levi-Montalcini R. 2005. Recombinant human nerve growth factor with a marked activity in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 102:18658-18663. http://dx.doi.org/10.1073/pnas.0508734102.
14. Philo JS, Rosenfeld R, Arakawa T, Wen J, Narhi LO. 1993. Refolding of brain-derived neurotrophic factor from guanidine hydrochloride: kinetic trapping in a collapsed form which is incompetent for dimerization. Biochemistry 32:10812-10818. http://dx.doi.org/10.1021/bi00091a036.
15. Hoshino K, Eda A, Kurokawa Y, Shimizu N. 2002. Production of brain-derived neurotrophic factor in Escherichia coli by coexpression of Dsb proteins. Biosci. Biotechnol. Biochem. 66:344-350. http://dx.doi.org/10.1271/bbb.66.344.
16. Fandl JP, Tobkes NJ, McDonald NQ, Hendrickson WA, Ryan TE, Nigam S, Acheson A, Cudny H, Panayotatos N. 1994. Characterization and crystallization of recombinant human neurotrophin-4. J. Biol. Chem. 269:755-759.
17. Nishizawa M, Ozawa F, Higashizaki T, Hirai K, Hishinuma F. 1993. Biologically active human and mouse nerve growth factors secreted by the yeast Saccharomyces cerevisiae. Appl. Microbiol. Biotechnol. 38:624-630.
18. Fukuzono S, Fujimori K, Shimizu N. 1995. Production of biologically active mature brain-derived neurotrophic factor in Escherichia coli. Biosci. Biotechnol. Biochem. 59:1727-1731. http://dx.doi.org/10.1271/bbb.59.1727.
19. Shusta EV, Holler PD, Kieke MC, Kranz DM, Wittrup KD. 2000. Directed evolution of a stable scaffold for T-cell receptor engineering. Nat. Biotechnol. 18:754-759. http://dx.doi.org/10.1038/77325.
20. Traxlmayr MW, Faissner M, Stadlmayr G, Hasenhindl C, Antes B, Rüker F, Obinger C. 2012. Directed evolution of stabilized IgG1-Fc scaffolds by application of strong heat shock to libraries displayed on yeast. Biochim. Biophys. Acta 1824:542-549. http://dx.doi.org/10.1016/j.bbapap.2012.01.006.
21. Kim YS, Bhandari R, Cochran JR, Kuriyan J, Wittrup KD. 2006. Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast. Proteins 62:1026-1035. http://dx.doi.org/10.1002/prot.20618.
22. Pepper LR, Cho YK, Boder ET, Shusta EV. 2008. A decade of yeast surface display technology: where are we now? Comb. Chem. High Throughput Screen. 11:127-134. http://dx.doi.org/10.2174/138620708783744516.
23. Pavoor TV, Cho YK, Shusta EV. 2009. Development of GFP-based biosensors possessing the binding properties of antibodies. Proc. Natl. Acad. Sci. U. S. A. 106:11895-11900. http://dx.doi.org/10.1073/pnas.0902828106.
24. Huang D, Shusta EV. 2005. Secretion and surface display of green fluorescent protein using the yeast Saccharomyces cerevisiae. Biotechnol. Prog. 21:349-357. http://dx.doi.org/10.1021/bp0497482.
25. Wentz AE, Shusta EV. 2007. A novel high-throughput screen reveals yeast genes that increase secretion of heterologous proteins. Appl. Environ. Microbiol. 73:1189-1198. http://dx.doi.org/10.1128/AEM.02427-06.
26. Boder ET, Wittrup KD. 1997. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15:553-557. http://dx.doi.org/10.1038/nbt0697-553.
27. Gietz RD, Woods RA. 2002. Transformation of yeast by lithium acetate/ single-stranded carrier DNA/polyethylene glycol method. Methods Enzymol. 350:87-96. http://dx.doi.org/10.1016/S0076-6879(02)50957-5.
28. Watson JV. 1992. Flow cytometry data analysis: basic concepts and statistics. Cambridge University Press, Cambridge, United Kingdom.
29. Tillotson BJ, Cho YK, Shusta EV. 2013. Cells and cell lysates: a direct approach for engineering antibodies against membrane proteins using yeast surface display. Methods 60:27-37. http://dx.doi.org/10.1016/j.ymeth.2012.03.010.
30. Colby DW, Kellogg BA, Graff CP, Yeung YA, Swers JS, Wittrup KD. 2004. Engineering antibody affinity by yeast surface display. Methods Enzymol. 388:348-358. http://dx.doi.org/10.1016/S0076-6879(04)88027-3.
31. Swers JS, Kellogg BA, Wittrup KD. 2004. Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display. Nucleic Acids Res. 32:e36. http://dx.doi.org/10.1093/nar/gnh030.
32. Zaccolo M, Williams DM, Brown DM, Gherardi E. 1996. An approach to random mutagenesis of DNA using mixtures of triphosphate derivatives of nucleoside analogues. J. Mol. Biol. 255:589-603. http://dx.doi.org/10.1006/jmbi.1996.0049.
33. Stemmer WP. 1994. DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution. Proc. Natl. Acad. Sci. U. S. A. 91:10747-10751. http://dx.doi.org/10.1073/pnas.91.22.10747.
34. Jaboin J, Kim CJ, Kaplan DR, Thiele CJ. 2002. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3=-kinase pathway. Cancer Res. 62:6756-6763.
35. Kaplan DR, Hempstead BL, Martin-Zanca D, Chao MV, Parada LF. 1991. The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science 252:554-558. http://dx.doi.org/10.1126/science.1850549.
36. Vesa J, Kruttgen A, Shooter EM. 2000. p75 reduces TrkB tyrosine autophosphorylation in response to brain-derived neurotrophic factor and neurotrophin 4/5. J. Biol. Chem. 275:24414-24420. http://dx.doi.org/10.1074/jbc.M001641200.
37. He XL, Garcia KC. 2004. Structure of nerve growth factor complexed with the shared neurotrophin receptor p75. Science 304:870-875. http://dx.doi.org/10.1126/science.1095190.
38. Pattarawarapan M, Burgess K. 2003. Molecular basis of neurotrophinreceptor interactions. J. Med. Chem. 46:5277-5291. http://dx.doi.org/10.1021/jm030221q.
39. Ellgaard L, Helenius A. 2003. Quality control in the endoplasmic reticulum. Nat. Rev. Mol. Cell Biol. 4:181-191. http://dx.doi.org/10.1038/nrm1052.
40. Acklin C, Stoney K, Rosenfeld RA, Miller JA, Rohde MF, Haniu M. 1993. Recombinant human brain-derived neurotrophic factor (rHuBDNF). Disulfide structure and characterization of BDNF expressed in CHO cells. Int. J. Pept. Protein Res. 41:548-552.
41. Schweickhardt RL, Jiang X, Garone LM, Brondyk WH. 2003. Structureexpression relationship of tumor necrosis factor receptor mutants that increase expression. J. Biol. Chem. 278:28961-28967. http://dx.doi.org/10.1074/jbc.M212019200.
42. Robinson RC, Radziejewski C, Spraggon G, Greenwald J, Kostura MR, Burtnick LD, Stuart DI, Choe S, Jones EY. 1999. The structures of the neurotrophin 4 homodimer and the brain-derived neurotrophic factor/ neurotrophin 4 heterodimer reveal a common Trk-binding site. Protein Sci. 8:2589-2597.
43. Naylor RL, Robertson AG, Allen SJ, Sessions RB, Clarke AR, Mason GG, Burston JJ, Tyler SJ, Wilcock GK, Dawbarn D. 2002. A discrete domain of the human TrkB receptor defines the binding sites for BDNF and NT-4. Biochem. Biophys. Res. Commun. 291:501-507. http://dx.doi.org/10.1006/bbrc.2002.6468.
44. Dechant G, Biffo S, Okazawa H, Kolbeck R, Pottgiesser J, Barde YA. 1993. Expression and binding characteristics of the BDNF receptor chick trkB. Development 119:545-558.
45. Boder ET, Midelfort KS, Wittrup KD. 2000. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc. Natl. Acad. Sci. U. S. A. 97:10701-10705. http://dx.doi.org/10.1073/pnas.170297297.
46. Ibanez CF, Ilag LL, Murray-Rust J, Persson H. 1993. An extended surface of binding to Trk tyrosine kinase receptors in NGF and BDNF allows the engineering of a multifunctional pan-neurotrophin. EMBO J. 12:2281-2293.
47. Ibanez CF, Ebendal T, Persson H. 1991. Chimeric molecules with multiple neurotrophic activities reveal structural elements determining the specificities of NGF and BDNF. EMBO J. 10:2105-2110.
48. Nieba L, Honegger A, Krebber C, Pluckthun A. 1997. Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng. 10:435-444. http://dx.doi.org/10.1093/protein/10.4.435.
49. Robinson RC, Radziejewski C, Stuart DI, Jones EY. 1995. Structure of the brain-derived neurotrophic factor/neurotrophin 3 heterodimer. Biochemistry 34:4139-4146. http://dx.doi.org/10.1021/bi00013a001.